[1]林国乔,郑德志,陈伟奇.康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究[J].眼科新进展,2018,38(11):1055-1058.[doi:10.13389/j.cnki.rao.2018.0248]
　LIN Guo-Qiao,ZHENG De-Zhi,CHEN Wei-Qi.Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(11):1055-1058.[doi:10.13389/j.cnki.rao.2018.0248]
点击复制

康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年11期
页码:
1055-1058
栏目:
应用研究
出版日期:
2018-11-05

文章信息/Info

Title:
Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion
作者:
林国乔; 郑德志; 陈伟奇
515041　广东省汕头市，汕头大学联合香港中文大学汕头国际眼科中心
Author(s):
LIN Guo-Qiao; ZHENG De-Zhi; CHEN Wei-Qi
Joint Shantou International Eye Center，Shantou University and the Chinese University of Hongkong，Shantou 515041，Guangdong Province，China
关键词:
视网膜分支静脉阻塞; 黄斑水肿; 康柏西普; 眼内注射
Keywords:
branch retinal vein occlusion; macular edema; Conbercept; intravitreal injection.
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0248
文献标志码:
A
摘要:
目的　观察玻璃体内注射康柏西普治疗视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）继发黄斑水肿的疗效。方法　回顾性病例系列研究。回顾我院确诊为BRVO继发黄斑水肿行玻璃体内注射康柏西普患者31例31眼；随访 7.9~12.8 (9.53±1.20)个月。对比治疗前后最佳矫正视力（best corrected visual acuity，BCVA）、黄斑中心视网膜厚度（central macular thickness，CMT）及黄斑中心凹厚度（macular thickness，MT）的变化，记录与药物和治疗方式相关的并发症发生情况。结果　治疗前BCVA为（0.72±0.37）LogMAR，末次复查BCVA提高至（0.46±0.38）LogMAR，治疗前后差异有统计学意义（t=4.24，P<0.001）。12例患者视力得到了提高，19例患者视力维持稳定。注药前CMT为（461.16±146.20）μm，MT为（571.58±242.27）μm；末次复查CMT下降为（264.68±90.41）μm，MT下降为（272.29±188.54）μm，治疗前后差异均有统计学意义（CMT：t=6.24，P<0.001；MT：t=5.42，P<0.001）。所有患者随访期间均未见玻璃体出血、视网膜脱离、持续高眼压和眼内炎等并发症发生。结论　玻璃体内注射康柏西普治疗BRVO继发黄斑水肿有一定疗效，可以改善视力、减轻黄斑水肿。
Abstract:
Objective　To observe the efficacy of intravitreal Conbercept injectionsinmacular edema secondary to branch retinal vein occlusion (BRVO).Methods　Retrospective case series study was conducted in 31 eyes of 31 patients with BRVO who received intravitreal injections of Conbercept and the data were collected in this study.The follow-up time was 7.9 to 12.8 months,with the average of (9.53±1.20)months.The best corrected visual acuity (BCVA),central macular thickness (CMT) and macular thickness (MT) before and after therapy were compared.And complications associated with medicine and treatment modality were also recorded during the follow-up.Results　The BCVA before therapy was (0.72±0.37)LogMAR and increased to (0.46±0.38)LogMAR at the last follow-up,which showed a statistical difference（t=4.24，P<0.001）.Furthermore,the visual acuity of 12 patients got improved and 17 patients kept stable.The CMT and MT before therapy were (461.16±146.20) μm and (571.58±242.27)μm,respectively.At the last follow-up,the CMT and MT decreased to (264.68±90.41)μm and (272.29±188.54)μm,respectively.There were significant statistical difference for both CMT and MT before and after surgery（CMT：t=6.24，P<0.001； MT：t=5.42，P<0.001）.Finally,no severe complication occurred during the follow-up,such as vitreous hemorrhage,retinal detachment,intraocular hypertension and endophthalmitis.Conclusion　Intravitreal injection of Conbercept shows a certain curative effect in macular edema secondary to BRVO,which can not only improve visual acuity but also reduce macular thickness.

参考文献/References:

［1］　YAU J W Y，LEE P，WONG T Y，BEST E，JENKINS A.Retinal vein occlusion：an approach to diagnosis，systemic risk factors and management［J］.Int Med J，2008，38(12)：904-910.
［2］　MCINTOSH R L，ROGERS S L，LIM L，CHEUNG N，WANG J J，MITCHEL P，et al.Natural history of central retinal vein occlusion：an evidence-based systematic review［J］.Ophthalmology，2010，117(6)：1113-1123.
［3］　ROGERS S L，MCINTOSH R L，LIM L，MITCHELL P，CHEUNG N，KOWALSKI J W，et al.Natural history of branch retinal vein occlusion：an evidence-based systematic review［J］.Ophthalmology，2010，117(6)：1094-1101.
［4］　FUNK M，KRIECHBAUM K，PRAGER F，BENESCH T，GEORGOPOULOS M，ZLABINGER G J，et al.Intraocular concentrations of growth factors and cytokinesin retinal vein occlusion and the effect of therapy with bevacizumab［J］.Invest Ophthalmol Vis Sci，2009，50(3)：1025-1032.
［5］　SONG W，XIA X.Ranibizumab for macular edema secondary to retinal vein occlusion：a meta-analysis of dose effects and comparison with no anti-VEGF treatment［J］.BMC Ophthalmol，2015，15：31.
［6］　BRAITHWAITE T，NANJI A，LINDSLEY K，GREENBERG P B.Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion［J］.Cochrane Database Syst Rev，2014，CD007325.
［7］　ZHANG M，ZHANG J，YAN M，LUO D，ZHU W，KAISER P K，et al.A phase1 study of KH902，a vascular endothelial growth factor receptor decoy，for exudative age-related macular degeneration［J］.Ophthalmology，2011，118(4)：672-678.
［8］　NOMA H，FUNATSU H，MIMURA T，HARINO S，HORI S.Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion［J］.Ophthalmology，2009，116(1)：87-93.
［9］　NOMA H，MINAMOTO A，FUNATSU H，TSUKAMOTO H，NAKANO K，YAMASHITA H，et al.Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2006，244(3)：309-315.
［10］　HEIER J S，CAMPOCHIARO P A，YAU L，LI Z，SAROJ N，RUBIO R G，et al.Ranibizumab for macular edema due to retinal vein occlusions：long-term follow-up in the HORIZON trial［J］.Ophthalmology，2012，119(4)：802-809.
［11］　BROWN D M，CAMPOCHIARO P A，SINGH R P，LI Z，GRAY S，SAROJ N，et al.Ranibizumab for macular edema following central retinal vein occlusion：six-month primary end point results of a phase III study［J］.Ophthalmology，2010，117(6)：1124-1133.
［12］　CAMPOCHIARO P A，HEIER J S，FEINER L，GRAY S，SAROJ N，RUNDLE A C，et al.Ranibizumab for macular edema following branch retinal vein occlusion：six-month primary end point results of a phase III study［J］.Ophthalmology，2010，117(6)：1102-1112.
［13］　MIWA Y，MURAOKA Y，OSAKA R，OOTO S，MURAKAMI T，SUZUMA K，et al.Ranibizumab for macular edema after branch retinal vein occlusion：One initial injection versus three monthly injections［J］.Retina，2017，37(4)：702-709.
［14］　AHN S J，AHN J，WOO S J，PARK K H.Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion［J］.Biomed Res Int，2013，2013：209735.
［15］　LU X，SUN X.Profile of conbercept in the treatment of neovascular age-related macular degeneration［J］.Drug Des Devel Ther，2015，9：311-320.
［16］　SUN Z，ZHOU H，LIN B，JIAO X，LUO Y，ZHANG F，et al.Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion［J］.Retina，2017，37(9)：1723-1730.
［17］　LI F，SUN M，GUO J，MA A，ZHAO B.Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion［J］.Curr Eye Res，2017，42(8)：1174-1178.
［18］　MAO J B，ZHU M Q，CHEN Y Q，ZHENG B，ZHANG Y，SHEN L J.The efficacy of intravitreal conbercept for macular edema secondary to retinal vein occlusion［J］.Chin J Ocul Fundus Dis，2016，32(4)：372-376.
毛剑波，褚梦琪，陈亦棋，郑斌，张赟，沈丽君.玻璃体腔注射康柏西普治疗视网膜静脉阻塞黄斑水肿短期疗效观察［J］.中华眼底病杂志，2016，32(4)：372-376.
［19］　ZHOU Y，ZHOU M，LIU H J，DING H X.Prospective randomized clinical trial on intravitreous injection of Conbercept for macular edema secondary to retinal vein occlusion［J］.Chin J Pract Ophthalmol，2016，34(6)：597-600.
周颖，周明，刘豪杰，丁海祥.康柏西普治疗视网膜静脉阻塞继发黄斑水肿临床观察［J］.中国实用眼科杂志，2016，34(6)：597-600.
［20］　KAMEI M，TERASAKI H，YOSHIMURA N，SHIRAGA F，OGURA Y，GROTZFELD A S，et al.Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients［J］.Acta Ophthalmol，2017，95(1)：e29-e35.
［21］　OGURA Y，ROIDER J，KOROBELNIK J，HOLZ F G，SIMADER C，SCHMIDT-ERFURTH U，et al.Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion：18-month results of the phase 3 GALILEO study［J］.Am J Ophthalmol，2014，158(5)：1032-1038.
［22］　CLARK W，BOYER D，HEIER J，BROWN D M，HALLER J A，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion：52-week results of the vibrant study［J］.Ophthalmology，2016，123(2)：330-336.
［23］　JAISSLE G B，SZURMAN P，FELTGEN N，SPITZER B，PIELEN E，REHAK M E，et al.Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol，2011，249(2)：183-192.

相似文献/References:

[1]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[2]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[3]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[4]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[5]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[6]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[7]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[8]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[9]魏光杰,何佃菊.532nm绿激光格栅样光凝联合球内注药治疗糖尿病视网膜病变黄斑水肿[J].眼科新进展,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
　WEI Guang-Jie,HE Dian-Ju.532 run green grid laser photocoagulation combined with intravitreal Avastin injection for diabetic retinopathy macular edema[J].Recent Advances in Ophthalmology,2014,34(11):779.[doi:10.13389/j.cnki.rao.2014.0215]
[10]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[11]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[12]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772.[doi:10.13389/j.cnki.rao.2014.0213]
　CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(11):772.[doi:10.13389/j.cnki.rao.2014.0213]
[13]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
　FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(11):270.[doi:10.13389/j.cnki.rao.2015.0072]
[14]李仕永,高瑞莹,陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效[J].眼科新进展,2016,36(12):1161.[doi:10.13389/j.cnki.rao.2016.0309]
　LI Shi-Yong,GAO Rui-Ying,CHEN Hui.Effects of ranibizumab ( Lucentis) intravitreal injection combined with retinal argon laser photocoagulation on macular edema secondary to different period of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(11):1161.[doi:10.13389/j.cnki.rao.2016.0309]
[15]刘广峰,洪婷婷,苗森,等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展,2017,37(7):658.[doi:10.13389/j.cnki.rao.2017.0167]
　LIU Guang-Feng,HONG Ting-Ting,MIAO Sen,et al.Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(11):658.[doi:10.13389/j.cnki.rao.2017.0167]
[16]石蕊,肖云芳,王峰,等.糖尿病合并视网膜分支静脉阻塞患者继发黄斑水肿后视力损伤程度及危险因素[J].眼科新进展,2017,37(12):1139.[doi:10.13389/j.cnki.rao.2017.0287]
　SHI Rui,XIAO Yun-Fang,WANG Feng,et al.Vision impairment following macular edema secondary to diabetes combined with branch retinal vein occlusion and its potential risk factors[J].Recent Advances in Ophthalmology,2017,37(11):1139.[doi:10.13389/j.cnki.rao.2017.0287]
[17]江慧娟,庞东渤.视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞（BRVO）致黄斑水肿的疗效[J].眼科新进展,2018,38(4):348.[doi:10.13389/j.cnki.rao.2018.0081]
　JIANG Hui-Juan,PANG Dong-Bo.Efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema induced by ischemic branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(11):348.[doi:10.13389/j.cnki.rao.2018.0081]
[18]赵芃芃,秦梅.视网膜分支静脉阻塞治疗研究现状[J].眼科新进展,2018,38(5):485.[doi:10.13389/j.cnki.rao.2018.0114]
　ZHAO Peng-Peng,QIN Mei.Treatment research status of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(11):485.[doi:10.13389/j.cnki.rao.2018.0114]
[19]杨大勇,李琳.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞（BRVO）继发黄斑水肿疗效观察[J].眼科新进展,2019,39(4):369.[doi:10.13389/j.cnki.rao.2019.0084]
　YANG Da-Yong,LI Lin.Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(11):369.[doi:10.13389/j.cnki.rao.2019.0084]
[20]尹小芳,叶祖科,汤秀容,等.玻璃体内注射雷珠单抗后视网膜分支静脉阻塞性黄斑水肿复发的危险因素分析[J].眼科新进展,2020,40(1):046.[doi:10.13389/j.cnki.rao.2020.0011]
　YIN Xiaofang,YE Zuke,TANG Xiurong,et al.Risk factors for recurrence of macular edema associated with branch retinal vein occlusions after intravitreal injection of Ranibizumab treatment[J].Recent Advances in Ophthalmology,2020,40(11):046.[doi:10.13389/j.cnki.rao.2020.0011]

备注/Memo

备注/Memo:
广东省医学科学技术研究基金资助（编号：B2016096）
更新日期/Last Update: 2018-10-30